An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Latest Information Update: 15 Dec 2022
Price :
$35 *
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 07 Dec 2022 Results of post hoc analysis assessing baseline clinical features associated with the outcomes of patients enrolled in the COMBI-MB phase II study of dabrafenib and trametinib treatment in patients with V600 BRAF-mutant metastatic melanoma with melanoma brain metastases published in the Clinical Cancer Research
- 23 Aug 2018 The status of the trial has been changed to discontinued.
- 22 Sep 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2018.